HYBRID EVENT: You can participate in person at Boston, Massachusetts, USA or Virtually from your home or work.
Mayra Ramos Suzarte, Speaker at Vaccines Conferences
Keynote Presentation (In-person)
Mayra Ramos Suzarte, Center of Molecular Immunology, Cuba

Lung cancer is the first cause of death from cancer in the world and in some countries as the first cause of death for both sexes. Early diagnosis and timely therapy is successful for increasing the survival of these patients, however, the masking with frequent symptoms of other [....] » Read More

Mayra Ramos Suzarte, Speaker at Vaccines Conferences
Keynote Presentation (In-person)
Mayra Ramos Suzarte, Center of Molecular Immunology, Cuba

COVID-19 continues to be a global health problem, it is a multifactorial disease characterized by a process of hyperinflammation. Itolizumab, a humanized anti-CD6 mAb, has the Emergency Use Authorization (UEA) for patients with this disease with signs of hyperinflammation. Method [....] » Read More

Stefan Gluck, Speaker at Vaccine Research Events
Keynote Presentation (In-person)
Stefan Gluck, Vice President, Global Medical Affairs at Celgene Corporation, United States

The idea of using the immune system to fight cancer is over 100 years old. (Paul Ehrlich’s “Magic Bullet”). New cellular and molecular approaches over the last 2 decades or so, led to a better understanding of the immune system. Our focus became the T cell, its [....] » Read More

Sushmita Koley, Speaker at Vaccines Conferences
Oral Presentation (In-person)
Sushmita Koley, Senior Scientist Bio-Rad Laboratories, United States

One of the crucial steps in deploying plasma therapy for COVID-19 has been the development of critical assays to detect SARS-CoV-2 antibodies and evaluate their potential suitability. Unfortunately, assays that assess neutralizing antibodies involve use of live SARS-CoV-2 virus i [....] » Read More

Regina Au, Speaker at Vaccines Conferences
Oral Presentation (In-person)
Regina Au, BioMarketing Insight, United States

When the COVID-19 Vaccine was developed, time was crucial and the pharmaceutical and biotechnology  companies primary goal was to get a vaccine out as soon as possible so people to get vaccinated in saving lives.  What wasn't considered which most large companies co [....] » Read More

Joe Smyser, Speaker at Vaccine Research Events
Oral Presentation (In-person)
Joe Smyser, The Public Good Projects, United States

Introduction: As the pandemic evolves and nations refocus on routine immunizations and vaccine-preventable outbreaks, it is critical to continue increasing vaccine demand. Misinformation threatens the success of vaccination programs across the world. Since 2017, The Public Good P [....] » Read More

Daniel Becker, Speaker at Vaccines Conferences
Oral Presentation (In-person)
Daniel Becker, KyooBe Tech GmbH, Germany

In the ongoing global Covid-19 aftermath, epidemics and pandemics triggered by microbial and viral pathogens remain a significant challenge for global vaccine production and worldwide supply. The Irradiation of target pathogens with low-energy electrons (LEEI) can reliably and [....] » Read More

Kashif Zulfiqar, Speaker at Vaccine Research Events
Oral Presentation (In-person)
Kashif Zulfiqar, Project Manager - NADRA, Pakistan

National Immunization Management System (NIMS) in Pakistan envisages to consolidate all immunization activities that are being carried out in the country, on a single intelligent platform including vaccination scheduling, vaccine administration, role based reporting, complaint [....] » Read More

Maduike Chiehiura Onwubiko Ezeibe, Speaker at Vaccines Conferences
Oral Presentation (In-person)
Maduike Chiehiura Onwubiko Ezeibe, Michael Okpara University of Agriculture, Nigeria

Viral diseases, cancers (tumors) and antimicrobial resistant infections are among the world`s biggest health challenges. Literature reveals, that HIV and COVID-19 virus (RNA viruses) are positively charged while DNA viruses and abnormal (tumor/infected) cells are negatively charg [....] » Read More

Fejiro Chinye Nwoko, Speaker at Vaccines Conferences
Oral Presentation (In-person)
Fejiro Chinye Nwoko, Nigeria Solidarity Support Fund, Nigeria

Background: The first set of vaccines arrived in Nigeria in March 2021. The National Primary Health Care Development Agency (NPHCDA) set out to vaccinate at least 70% percent of Nigeria’s eligible population i.e., 111,776,503 people, by December 2022. As of June 2021, only [....] » Read More

Nebiyu Lera Alaro, Speaker at Immunology Conferences
Oral Presentation (In-person)
Nebiyu Lera Alaro, Medecins Sans Frontieres, Ethiopia

Most global estimates indicate that more than 1 million children a year die from acute measles. The actual number of deaths may, however, be considerably higher than this. In addition, the impact of delayed mortality as a result of measles infection is only now being realized. Ma [....] » Read More

Carless Gyamfuaa Ameyaw, Speaker at Vaccine Research Events
Oral Presentation (In-person)
Carless Gyamfuaa Ameyaw, Holy Family Hospital, Ghana

Background: The contribution of immunization to humanity is invaluable, especially to children. This makes assessment of the vaccine cold chain system of any immunization programme crucial to determine its strengths and weaknesses at all levels. The World Health Organization and [....] » Read More

Indira Acharya, Speaker at Vaccine Development Congress
Oral Presentation (In-person)
Indira Acharya, Medstar, United States

however ANA, rheumatoid factor Reactive arthritis after various vaccinations has been previously described but such kind of reaction after mpox vaccination has not been previously reported. Here we present a case of recently diagnosed reactive arthritis following intradermal mpox [....] » Read More

Malika Aid, Speaker at Immunology Conferences
Oral Presentation (In-person)
Malika Aid, Harvard School of Medicine, United States

Syrian golden hamsters exhibit features of severe disease after SARS-CoV-2 WA1/2020 challenge and are therefore useful models of COVID-19 pathogenesis and prevention with vaccines. Recent studies have shown that SARS-CoV-2 infection stimulates type I interferon, myeloid, and infl [....] » Read More

Temesgen Anjulo Ageru, Speaker at Vaccine Research Events
Oral Presentation (In-person)
Temesgen Anjulo Ageru, Wolaita Sodo University Comprehensive Specialized Hospital, Ethiopia

Background: Antibiotic resistance is a serious threat to the human population everywhere. However, less attention is given to its concern in sub-Saharan Africa including Ethiopia. There is an information gap concerning antibiotic resistance and its pattern in Wolaita Sodo Univers [....] » Read More

Shoukat Parvez, Speaker at Immunology Conferences
Oral Presentation (In-person)
Shoukat Parvez, The University of Faisalabad, Pakistan

COVID-19 is pandemic disease which is caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2SARS-CoV-2 was first identified in China in 20119, and subsequently spread world over.  The lack of a vaccine or curative treatment for COVID-19 necessi [....] » Read More

Getahun Fetensa, Speaker at Vaccine Development Congress
Oral Presentation (In-person)
Getahun Fetensa, School of Nursing and Midwifery, Ethiopia

Introduction: Vaccination is one of the most crucial strategies in the control of pandemics such as COVID-19. Although a couple of research has been conducted to assess the willingness of the population to accept the COVID-19 vaccine, the findings are inconsistent and inconclusiv [....] » Read More

Ouambo Fotso Herve, Speaker at Vaccine Development Congress
Oral Presentation (In-person)
Ouambo Fotso Herve, Centre International De Reference Chantal Biya, Cameroon

Introduction: In areas with intense perennial malaria transmission, limited data is available on the impact of environmental conditions especially rainfall on antibody responses against malaria vaccine candidates. For this reason, we have compared IgG antibody responses specific [....] » Read More

Kaleem Ullah Khan, Speaker at Vaccines Conferences
Oral Presentation (In-person)
Kaleem Ullah Khan, Polio Eradication and routine immunization program, Pakistan

Vaccine hesitancy: we do have a lot of issues from the community which make them hesitant towards vaccination process, includes disinformation about the vaccination spread by the community instigators play important role in this regards apart from that we do have a lot of religio [....] » Read More

Dereje Gashaw Andargie, Speaker at Immunology Conferences
Oral Presentation (In-person)
Dereje Gashaw Andargie, Bahirdar University, Ethiopia

Anaplastic thyroid cancer is a very aggressive tumor that advances quickly. Women and seniors are the most affected. After diagnosis, the median survival time is no longer than 6 to 8 months. Case presentation A 60-year-old female patient from the northwest of Ethiopia was ad [....] » Read More

Levast Benoit , Speaker at Vaccines Conferences
Oral Presentation (In-person)
Levast Benoit , BIOASTER, France

The emergence of multiple SARS-CoV-2 variants as well as the implementation of different vaccination strategies gave rise to multiple immunization schemes in the population and related questions: which immunization strategy leads to the most effective long-term immune response ag [....] » Read More

Kristen Lee Moriarty, Speaker at Vaccine Research Events
Oral Presentation (In-person)
Kristen Lee Moriarty, UCONN Health, United States

The National Institute of Health recommends Nirmatrelvir-Ritonavir (NIR) treatment for pregnant patients with COVID-19. However, little is known about NIR treatment acceptance rates in pregnant patients and what strategies may increase access and acceptance rates of NIR treatment [....] » Read More

Nzolameso makaya Jennifer, Speaker at vaccine conferences
Poster Presentation (In-person)
Nzolameso makaya Jennifer, Hopital General De Reference De Kimbanseke Pierre Pokom, Congo

70% of people over 65 are hypertensive; high blood pressure increases the risk of exposure to cardiovascular disease (myocardial infarction and heart failure) and stroke. This is a public health problem, given the aging of the population. There are few studies carried out in e [....] » Read More

Vincent Omondi, Speaker at Vaccine Research Events
Poster Presentation (In-person)
Vincent Omondi, Clinton Health Access Initiative, Kenya

The COVID-19 pandemic has had a significant impact on global healthcare services, including routine immunization programs. In particular, the pandemic has disrupted human papillomavirus (HPV) vaccination efforts, which are critical in preventing HPV-related cancers. This review e [....] » Read More

Khalid Jebril Shrwani, Speaker at Vaccine Research Events
Poster Presentation (In-person)
Khalid Jebril Shrwani, Public Health Authority, Saudi Arabia

Middle East respiratory syndrome coronavirus (MERS-CoV) has emerged as a deadly pathogen with a mortality rate of up to 34.4% that can cause severe respiratory tract disease and multiorgan failure. Therefore, there is a pressing need for both successful antiviral vaccines and eff [....] » Read More

Tanvir Hossen, Speaker at Vaccine Research Events
Poster Presentation (In-person)
Tanvir Hossen, Expanded Program on Immunization (EPI), Bangladesh

For several years, outreach immunization sessions in Bangladesh were hosted in the homes of individuals. Vaccinators called Health Assistants would sit in the living rooms or house yards of local community members, including mullahs and other leaders, while caregivers would gathe [....] » Read More

Tripti Pal Raman, Speaker at Vaccine Development Congress
Poster Presentation (In-person)
Tripti Pal Raman, World Health Organization, Nepal

In Nepal significant increase of zero dose children from1% to 4% have alerted all the stakeholders associated with child immunization1 . In addition to this increasing outbreak of vaccine preventable diseases in the areas with low vaccination dose are showing importance of increa [....] » Read More

Mansour Nazari, Speaker at Vaccines Conferences
Poster Presentation (In-person)
Mansour Nazari, Hamadan University of Medical Sciences, Iran (Islamic Republic of)

Objectives:  The cockroaches are the most important Transmitter of Pathogenic pathogens. The presence of cockroaches as insects that are free to move outside and inside hospitals can lead to pathogenic bacteria, which are considered as one of the problems of health devices a [....] » Read More

Ismail, Speaker at Vaccine Development Congress
Poster Presentation (In-person)
Ismail, Globe Biotech ltd,Bangladesh, Bangladesh

The devastating novel coronavirus (COVID-19) pandemic worldwide has become a global health crisisThis disease is highly contagious and caused by the transmission of severe acute respiratory syndrome, coronavirus 2 (SARS-CoV-2). To prevent the transmission of SARS-CoV-2, disinfect [....] » Read More

Lev Ramirez, Speaker at Vaccine Research Events
Poster Presentation (In-person)
Lev Ramirez, Universidad de La Sabana , Colombia

In the wake of the COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2), the global healthcare landscape has undergone a profound transformation. This transformation has been marked by the rapid development and deployment of COVID-19 vaccines [....] » Read More

Hye Jin Kim, Speaker at Vaccine Research Events
Poster Presentation (In-person)
Hye Jin Kim, Division of Clinical Vaccine Research, Korea, Republic of

B cells and T cells are known to play important roles during severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and vaccination. To understand changes in immune response to SARS-CoV-2 vaccination, changes in single cell RNA sequencing were conducted in serial [....] » Read More

Sudhakar Bangera, Speaker at Vaccines Conferences
Keynote Presentation
Sudhakar Bangera, Fellow-vaccinology managing partner AILEEN clinical research services AILEEN, India

It’s not just the bacteria or viruses that most commonly cause life-threatening disease in human, some of them could be fungal pathogens. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infe [....] » Read More

Khursheed Anwer, Speaker at Immunology Conferences
Oral Presentation (In-person)
Khursheed Anwer, IMUNON, Inc., United States

This presentation describes the development of PLACCINE a novel DNA vaccine platform well-suited to overcome the limitations of the current vaccines.  The PLACCINE platform leverages the inherent DNA advantages including design flexibility incorporating multi-antigen payload [....] » Read More

Jennifer Elaine Gerber, Speaker at Speaker for Vaccine Conferences- Jennifer Elaine Gerber
Oral Presentation (Virtual)
Jennifer Elaine Gerber, Johns Hopkins Bloomberg School of Public Health, United States

Background: Vaccine coverage is lower for influenza than for other vaccines, varying by age, race/ethnicity, and region. Vaccine safety concerns are common despite a lack of epidemiological evidence. We characterized vaccine hesitancy and identified associations with influenza va [....] » Read More

Paul Van Buynder, Speaker at Vaccine Research Events
Oral Presentation (Virtual)
Paul Van Buynder, Griffith University, Australia

Immune senescence and inflammaging render older persons more susceptible to severe consequences of infectious diseases and likely to exhibit poorer responses to vaccination.  Older persons need influenza, pneumococcal, herpes zoster, pertussis and SARS-CoV-2 vaccines and soo [....] » Read More

Patricia Canteri de Souza, Speaker at Vaccine Research Event
Oral Presentation (Virtual)
Patricia Canteri de Souza, State University of Londrina, Brazil

The production, extraction, and use of antibodies from birds is an innovative methodology that supports several purposes, from passive immunotherapy to prophylaxis and diagnosis of diseases. Immunoglobulins Y (IgY), produced by chickens, are functionally similar to immunoglobulin [....] » Read More

Yacob Mathai, Speaker at Vaccines Conferences
Oral Presentation (Virtual)
Yacob Mathai, Marma Health Centre, India

Medical textbooks say that modern science does not know enough about fever and there is no uniform definition. Physicians do not know the purpose of fever. Because fever is believed to be dangerous to the body, modern science has not looked at what our bodies have done wi [....] » Read More

Godwin Pancras, Speaker at Vaccines Conferences
Oral Presentation (Virtual)
Godwin Pancras, Muhimbili University of Health and Allied Sciences, Tanzania, United Republic of

Making proven intervention available to the host community is increasingly becoming a moral obligation than a researcher’s discretion. This study aimed to explore whether host communities of HIV vaccine trials ought to access the vaccines at no or subsidized princes. A case [....] » Read More

Ming Chung Kan, Speaker at Immunology Conferences
Oral Presentation (Virtual)
Ming Chung Kan, Founder of Vaxsia Biomedical Inc, Taiwan

Vaxsia has developed a self-assembled protein nanoparticle (PNP) platform, VADEX. The building block of VADEX is a fusion protein contains two functional modules: polymerization module and antigen presentation module. The polymerization module is modified from an amphipathic heli [....] » Read More

Mohammad Zorriehzahra, Speaker at Vaccines Conferences
Oral Presentation (Virtual)
Mohammad Zorriehzahra, Iranian Fisheries Science Research Institute , Iran (Islamic Republic of)

Today, with the development of technology and the expansion of genomics, the vaccine design process has been transferred from laboratory and practical research to the workroom and designs based on bioinformatics and genomic studies. This change has reduced costs and eliminated ex [....] » Read More

Ahsan Ahmed, Speaker at Vaccine Research Events
Oral Presentation (Virtual)
Ahsan Ahmed, KPC Medical College & Hospital, India

In this lecture, I want to talk about the role of vaccine in critically ill adult patients in ICU – How different vaccines are directly or indirectly help in reducing disease severity and morbidity of certain disease which are otherwise associated with high morbidity and mo [....] » Read More

Owais, Speaker at Vaccine Development Congress
Oral Presentation (Virtual)
Owais, Aligarh Muslim University, India

The scourge of tuberculosis and other intracellular infection is continuing to toll millions of human lives annually. Unfortunately, in the present scenario we are not having effective vaccines against most of the intracellular infections. For example, the only vaccine against tu [....] » Read More

Bethan Charlotte Hussey, Speaker at Vaccines Conferences
Oral Presentation (Virtual)
Bethan Charlotte Hussey, UK Health Security Agency, United Kingdom

The UK Health Security Agency (UKHSA) has longstanding expertise in the technological support of vaccine development through a vast array of immunological assays. In early 2020, using this valuable knowledge, scientists within UKHSA were able to rapidly develop a live virus micro [....] » Read More

Miranda Baxa, Speaker at Immunology Conferences
Oral Presentation (Virtual)
Miranda Baxa, Economist Impact, United States

In our interconnected modern world, diseases like covid-19 threaten global security and global development. More must be done to generate the political will to secure adequate, sustainable investment in vaccines and ensure equitable access around the world. The Immunisation Re [....] » Read More

Tianshuo Zhao, Speaker at Vaccines Conferences
Oral Presentation (Virtual)
Tianshuo Zhao, Peking University, China

Background: As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) attenuates and antibodies from the coronavirus disease 2019 (COVID-19) vaccine decline, long-term attention should be paid to the durability of primary-booster administration and the preventive effect [....] » Read More

Lucke Wold Brandon, Speaker at Vaccine Research Events
Oral Presentation (Virtual)
Lucke Wold Brandon, Baylor University, United States

Neonatal sepsis is a bloodstream infection that affects newborn infants under the age of 28 days and is a leading cause of morbidity and mortality in these children 1,2. There is little information on the prevalence of newborn sepsis, however Fleischmann-Struzek et al. estim [....] » Read More

Abhisek Routray, Speaker at Vaccine Development Congress
Oral Presentation (Virtual)
Abhisek Routray, Medical Advisor , India

S. pneumoniae ranks as the fourth most lethal pathogen globally in terms of fatalities associated with or attributable to resistance. ATLAS surveillance study from India aims to study the overall antimicrobial susceptibility (AMS) among pneumococcal isolates collected between 201 [....] » Read More

 Whegang Youdom Solange, Speaker at Immunology Conferences
Oral Presentation (Virtual)
Whegang Youdom Solange, Department of public health/Faculty of Medicine , Cameroon

Complete childhood vaccination remains poor in Sub-Saharan African countries. Although missed opportunity for vaccination (MOV) was found responsible for low coverage, median time-to-corrected is useful to assess delay in vaccination. MOV also reflects quality of immunization ser [....] » Read More

Anshuman Shukla, Speaker at Vaccines Conferences
Oral Presentation (Virtual)
Anshuman Shukla, Principal Medical Writer, Malaysia

The development of efficient vaccine delivery systems is critical to enhance immunization strategies and combat a wide array of infectious diseases. Mucosal vaccines have emerged as a promising approach, leveraging the body's natural immune response at the site of pathogen en [....] » Read More

Yasser Mohammed Hassanain, Speaker at Vaccine Development Congress
Oral Presentation (Virtual)
Yasser Mohammed Hassanain, Egyptian Ministry of Health, Egypt

Rationale: Drug-associated adverse effects are one of the most important entities in clinical medicine. Involuntary movements may have a dynamic serious impact on myocardial muscle. Myoclonus is well abnormal involuntary movements with a distinct description. Myoclonus is a physi [....] » Read More

Yitong Yang, Speaker at Immunology Conferences
Oral Presentation (Virtual)
Yitong Yang, Suzhou High School of Jiangsu Province, China

This study aimed to systematically review the facilitators and barriers influencingHPVvaccineaccessibility among women in China. The analysis is based on a synthesis of 24 relevant studies,focusing on key factors such as geographic disparities, knowledge gaps, populationdemograph [....] » Read More

Ali Abbaszade Cheragheali, Speaker at Vaccine Development Congress
Oral Presentation (Virtual)
Ali Abbaszade Cheragheali, Torbat Heydariyeh University of Medical Sciences, Iran (Islamic Republic of)

Infectious diseases continue to pose a significant threat to global public health, highlighting the critical need for effective prevention strategies. Vaccination has long been recognized as one of the most successful and cost-effective interventions in the fight against infectio [....] » Read More

Homoud Salem Aledhi Alrashidi, Speaker at Vaccines Conferences
Poster Presentation (Virtual)
Homoud Salem Aledhi Alrashidi, King Salman Hospital, Saudi Arabia

In December 2019, the coronavirus disease 2019 (COVID-19) first became identified in the market places of Wuhan, China. The first incidence of COVID-19 was identified in Saudi Arabia on March 2, 2020, and then within a month, the total number of reported instances had risen to ov [....] » Read More

Khalid Abd El Ghany, Speaker at Vaccines Conferences
Poster Presentation (Virtual)
Khalid Abd El Ghany, Post Doctor and Associate at Egyptian Drug Authority, Egypt

During the current era of the COVID-19 pandemic, the dissemination of Mucorales has been reported globally, with elevated rates of infection in India, and because of the high rate of mortality and morbidity, designing an effective vaccine against mucormycosis is a major health pr [....] » Read More

Ndjitoyap Ndam Antonin Wilson, Speaker at Vaccine Development Congress
Poster Presentation (Virtual)
Ndjitoyap Ndam Antonin Wilson, Department of Internal Medicine and Specialities, Cameroon

The hepatitis B virus infection remains a major public health problem worldwide. It can lead to a liver cirrhosis and/or hepatocellular carcinoma. The World Health Organization (WHO) has recommended the implementation of generalized vaccination programs against hepatitis B. In Ca [....] » Read More

Olivia Viscuso, Speaker at Vaccines Conferences
Poster Presentation (Virtual)
Olivia Viscuso, Mccombs School of Business at the University of Texas at Austin, United States

Introduction In recent years, politics and business have become increasingly intertwined, with employees increasingly seeking workplaces that align with their political views (Stuckatz, 2020). The COVID-19 pandemic response introduced public health regulations that became cont [....] » Read More

Joana Kira Besecke, Speaker at Vaccines Conferences
Poster Presentation (Virtual)
Joana Kira Besecke, Fraunhofer Institute for Organic Electronics, Germany

The use of low-energy electron irradiation (LEEI) is a novel and highly efficient method for manufacturing vaccines and other pharmaceutical products. This technology provides advantages against conventional methods for virus inactivation, as the process is faster, does not requi [....] » Read More

Narjes Noori Goodarzi, Speaker at Vaccine Development Congress
Poster Presentation (Virtual)
Narjes Noori Goodarzi, Tehran University of Medical Sciences, Iran (Islamic Republic of)

Gonorrhea is an urgent antimicrobial resistance threat and its therapeutic options are continuously getting restricted. Moreover, no vaccine has been approved against it so far. Hence, the present study aimed to introduce novel immunogenic and drug targets against antibiotic-resi [....] » Read More

Sonal Gidwani, Speaker at Vaccines Conferences
Poster Presentation (Virtual)
Sonal Gidwani, Calder Biosciences Inc, United States

Viral fusion proteins enable cellular infection by fusing viral and cellular membranes accompanied by their transition from the pre-fusion to the post-fusion conformation during viral entry.  Fusion proteins in their prefusion conformation elicit high neutralizing antibodies [....] » Read More

Devarshi Brahmbhatt, Speaker at Immunology Conferences
Poster Presentation (Virtual)
Devarshi Brahmbhatt, Calder Biosciences Inc, United States

Viral fusion proteins enable cellular infection by fusing viral and cellular membranes accompanied by their transition from the pre-fusion to the post-fusion conformation during viral entry.  Fusion proteins in their prefusion conformation elicit high neutralizing antibodies [....] » Read More

Diego Tomassone, Speaker at Vaccines Conferences
Poster Presentation (Virtual)
Diego Tomassone, Holos medica clinical and research, Italy

Recent advances in genomic and bioinformatic technologies have enabled the emergence of the field of immunogenomics. This intersection of immunology and genetics has expanded our understanding of how the immune system responds to infection and vaccination. While the immunogenetic [....] » Read More

Scientific Programs coming soon..

Watsapp